- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Relief Therapeutics Holding SA: Relief Therapeutics Holding SA Announces Results of Extraordinary General Meeting | 253 | EQS Group (EN) | Relief Therapeutics Holding SA
/ Key word(s): AGMEGM
RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary General Meeting
26.04.2024 / 17:30 CET/CEST
RELIEF... ► Artikel lesen | |
| 03.04. | Relief Therapeutics Holding SA - 6-K, Report of foreign issuer | 16 | SEC Filings | ||
| 27.03. | Relief Therapeutics Holding SA - 6-K, Report of foreign issuer | 11 | SEC Filings | ||
| 27.03. | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Holding SA to Hold Extraordinary General Meeting | 634 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): AGMEGM
RELIEF THERAPEUTICS Holding SA to Hold Extraordinary General Meeting
27-March-2024 / 07:00 CET/CEST
Release of an ad hoc announcement... ► Artikel lesen | |
| 22.03. | Relief Therapeutics grants exclusive U.S. rights to Eton Pharmaceuticals for PKU GOLIKE | 3 | Seeking Alpha | ||
| 22.03. | Eton Pharma Buys U.S. Rights To PKU GOLIKE From Relief Therapeutics | 4 | RTTNews | ||
| 22.03. | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE | 1.603 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Partnership
Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE
22-March-2024... ► Artikel lesen | |
| 28.02. | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Renews CHF 50 million Share Subscription Facility | 582 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Financing
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
28-Feb-2024 / 06:45 CET/CEST
Release of an ad hoc announcement... ► Artikel lesen | |
| 05.12.23 | Relief Therapeutics Holding SA - 6-K, Report of foreign issuer | 29 | SEC Filings | ||
| 05.12.23 | Relief Therapeutics will sich künftig auf Forschung & Entwicklung konzentrieren | 545 | Moneycab | Das Biotechunternehmen will sich künftig auf F&E konzentrieren. Dazu sollen die Produkte im kommerziellen Stadium schrittweise auf ein Partnerschaftsmodell umgestellt werden.Genf - Das Biotechunternehmen... ► Artikel lesen | |
| 05.12.23 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth | 1.343 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Miscellaneous
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth
05-Dec-2023... ► Artikel lesen | |
| 22.11.23 | Relief Therapeutics Holding SA - 6-K, Report of foreign issuer | 12 | SEC Filings | ||
| 22.11.23 | Relief Therapeutics announces CEO transition | 3 | Seeking Alpha | ||
| 22.11.23 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Announces CEO Transition | 1.342 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Personnel
Relief Therapeutics Announces CEO Transition
22-Nov-2023 / 08:40 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53... ► Artikel lesen | |
| 10.10.23 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Announces that more than 400,000 of its ADRs are currently outstanding and that, as a result, the Company has achieved an Important NASDAQ Initial Listing Milestone | 1.296 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Miscellaneous
Relief Therapeutics Announces that more than 400,000 of its ADRs are currently outstanding and that, as a result, the Company... ► Artikel lesen | |
| 15.09.23 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Reports Half-Year 2023 Financial Results and Provides Corporate Update | 1.745 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Half Year Results
Relief Therapeutics Reports Half-Year 2023 Financial Results and Provides Corporate Update
15-Sep-2023 / 07:00 CET/CEST
Release... ► Artikel lesen | |
| 01.09.23 | Relief Therapeutics Holding SA: Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference | 603 | EQS Group (EN) | Relief Therapeutics Holding SA
/ Key word(s): Conference
Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
01.09.2023... ► Artikel lesen | |
| 30.08.23 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Announces New Exclusive Definitive License Agreement for OLPRUVA (ACER-001) with Acer Therapeutics | 2.304 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Agreement/Product Launch
Relief Therapeutics Announces New Exclusive Definitive License Agreement for OLPRUVA (ACER-001) with Acer Therapeutics... ► Artikel lesen | |
| 19.07.23 | Relief Therapeutics Holding SA: Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE® in the U.S. with Pentec Health | 1.082 | EQS Group (EN) | Relief Therapeutics Holding SA
/ Key word(s): Agreement/Product Launch
Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE® in the U.S.... ► Artikel lesen | |
| 23.06.23 | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics and World Orphan Drug Alliance Announce an Exclusive, Long-Term, Distribution Agreement to Introduce PKU GOLIKE® in the Middle East | 2.188 | EQS Group (EN) | Relief Therapeutics Holding SA / Key word(s): Agreement/Product Launch
Relief Therapeutics and World Orphan Drug Alliance Announce an Exclusive, Long-Term, Distribution Agreement... ► Artikel lesen |
Seite:
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| REVIVE THERAPEUTICS | 0,030 | +195,00 % | Revive Therapeutics Ltd.: Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID | TORONTO, April 23, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research... ► Artikel lesen | |
| MORPHOSYS | 65,65 | -3,24 % | EQS-PVR: MorphoSys AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: MorphoSys AG
MorphoSys AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
22.04.2024 / 16:00 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| EVOTEC | 9,625 | +4,22 % | Aufholjagd BioTech 2024 - jetzt positionieren! Bayer, BioNTech, Defence Therapeutics, Evotec, BioNxt und Vidac Pharma im Fokus | BioTech-Investoren haben im Jahr 2024 bislang noch keine große Party feiern können. Das blieb eher den Spekulanten in den Sektoren Künstliche Intelligenz und Rüstung vorbehalten. Doch nun neigen sich... ► Artikel lesen | |
| QIAGEN | 39,145 | +0,99 % | Biotech Report: Sektor fester - Evotec und Qiagen können zulegen | (shareribs.com) Frankfurt / New York 22.04.2024 - Biotech-Aktien verzeichneten zum Wochenauftakt im deutschen Handel Kursgewinne. Gesucht waren unter anderem Evotec und Qiagen. Auch an der Wall Street... ► Artikel lesen | |
| JANUX THERAPEUTICS | 56,08 | 0,00 % | Janux Therapeutics jumps as much as 28% on heels of Deciphera buyout deal | ||
| SPRINGWORKS THERAPEUTICS | 46,450 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | ||
| IMMUNOVANT | 27,490 | 0,00 % | Should You Hold Immunovant (IMVT)? | ||
| CABALETTA BIO | 10,480 | 0,00 % | Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update | - First patient dosed with CABA-201 in the RESET (REstoring SElf-Tolerance) clinical trial program - - Initial clinical data from each of the first patients in the RESET-Myositis and RESET-SLE trials... ► Artikel lesen | |
| VERA THERAPEUTICS | 41,380 | 0,00 % | Aktien New York Ausblick: Vor dem Start in die Berichtssaison stabil erwartet | NEW YORK (dpa-AFX) - Nach einem schwachen Handelsverlauf am Vortag dürften sich die US-Börsen am Donnerstag stabilisieren. Am Mittwoch hatte eine überraschend hohe Inflation im Monat März die Hoffnungen... ► Artikel lesen | |
| NUVALENT | 67,95 | +1,63 % | Nuvalent, Inc.: Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024 | Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile
Zidesamtinib shown to... ► Artikel lesen | |
| ARCELLX | 51,11 | 0,00 % | Should You Be Bullish on Arcellx (ACLX)? | ||
| CULLINAN THERAPEUTICS | 27,120 | +7,19 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer | CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the appointment... ► Artikel lesen | |
| BIONTECH | 83,85 | +1,76 % | BioNTech Aktie: Trendwende oder Trugschluss? | Die BioNTech-Aktie hat mit einem jüngsten Kurs von 82,05 € und einer Wochenveränderung von 0,67% eine marginale Erholung erfahren, nachdem sie in der Vergangenheit sinkende Kurse verkraften musste.... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 8,200 | 0,00 % | Recursion Pharmaceuticals' Options Frenzy: What You Need to Know | ||
| BEAM THERAPEUTICS | 22,050 | +3,23 % | Expert Ratings For Beam Therapeutics |
RELIEF THERAPEUTICS HOLDING AG ADR gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 2,107 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
